Project Title: An Independent Prognostic Marker for Cancer Patients.
 
Acronym: STELA
 
Call: UK Investment Accelerator Pilot
 
Start Date: 01/10/2017
 
Duration: 12 months
 
Grant Amount: £130,636
 
Our Role: Bid Writing

TeloNostiX is developing a disruptive technology called Single Telomere Length Analysis which can predict the outcome of common cancer types, e.g. Chronic Lymphocytic Leukemia (CLL), and identify patients who do and do not require early treatment; a precision hitherto impossible to achieve. STELA is >6 times more powerful than any market competitor as a prognostic biomarker and can predict patient response to “gold standard” treatment.
 
The project demonstrated the technical feasibility of telomere testing in the routine clinical management of patients suffering from CLL by performing a logistical evaluation within an operational environment. Secondly, it created a financial justification for NHS adoption of STELA by undertaking health economics modelling. Finally, it afforded TeloNostiX to engage with a global distributor of telomere tests and analyse the cancer prognostics market using current market reports to further quantify the business opportunity.